LIVMARLI cuts bile acids 70% in Phase 3. Can Mirum turn its biliary atresia breakthrough into FDA approval?
Mirum's LIVMARLI meets its Phase 3 itch endpoint and cuts bile acids, supporting a planned 2027 FDA filing for rare liver diseases.
Pharma & Biotech